Petros Pharmaceuticals Files S-1 with SEC

TL;DR

Petros Pharma dropped an S-1 on the SEC, get ready for the deets.

AI Summary

Petros Pharmaceuticals, Inc. filed an S-1 form on January 24, 2025, detailing its financial status and business operations. The company, incorporated in Delaware with its principal office in New York, operates in the pharmaceutical preparations sector. Key financial data and disclosures related to its fiscal year ending December 31 are included in this filing.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Petros Pharmaceuticals' financial health and strategic direction, impacting potential investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, there are inherent risks associated with regulatory approvals, market competition, and financial performance typical of the sector.

Key Numbers

• 333-284495 — SEC File Number (Identifies the specific SEC registration statement)
• 25554898 — Film Number (Internal SEC processing number for the filing)

Key Players & Entities

• Petros Pharmaceuticals, Inc. (company) — Filer of the S-1 document
• 20250124 (date) — Filing date of the S-1
• 1185 AVENUE OF THE AMERICAS, 3RD FLOOR (address) — Business and mailing address of Petros Pharmaceuticals
• New York (location) — City of Petros Pharmaceuticals' business address
• DE (location) — State of incorporation for Petros Pharmaceuticals
• 1231 (date) — Fiscal year end for Petros Pharmaceuticals

FAQ

Key Financial Figures

• $0.0001 — nsisting of shares of our common stock, $0.0001 par value per share ("common stock"), S
• $0.345 — stock on The Nasdaq Capital Market was $0.345 per share. We are an "emerging growth
• $125,000 — t-of-pocket expenses in an amount up to $125,000. See " Plan of Distribution " for a des

Filing Documents

• tmb-20240930xs1.htm (S-1) — 4839KB
• tmb-20240930xex23d1.htm (EX-23.1) — 3KB
• tmb-20240930xex23d2.htm (EX-23.2) — 3KB
• tmb-20240930xexfees.htm (EX-FILING FEES) — 96KB
• tmb-20240930xs1002.jpg (GRAPHIC) — 12KB
• 0001410578-25-000047.txt ( ) — 20248KB
• tmb-20240930.xsd (EX-101.SCH) — 125KB
• tmb-20240930_cal.xml (EX-101.CAL) — 77KB
• tmb-20240930_def.xml (EX-101.DEF) — 501KB
• tmb-20240930_lab.xml (EX-101.LAB) — 782KB
• tmb-20240930_pre.xml (EX-101.PRE) — 962KB
• tmb-20240930xs1_htm.xml (XML) — 3046KB

USE OF PROCEEDS

USE OF PROCEEDS 41 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 42 CAPITALIZATION 43

DILUTION

DILUTION 45 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 47

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 50

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 56 MATERIAL US FEDERAL INCOME TAX CONSEQUENCES 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 69 PLAN OF DISTRIBUTION 70

MANAGEMENTS DISCUSSION AND ANALYSIS

MANAGEMENTS DISCUSSION AND ANALYSIS 77 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 100 EXECUTIVE AND DIRECTOR COMPENSATION 107 PRINCIPAL STOCKHOLDERS 111 EXPERTS 114 LEGAL MATTERS 114 WHERE YOU CAN FIND MORE INFORMATION 114

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision. You should rely only on the information provided in this prospectus. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find Additional Information." We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that o

View Full Filing

View this S-1 filing on SEC EDGAR